JP2021513552A - 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 - Google Patents

非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 Download PDF

Info

Publication number
JP2021513552A
JP2021513552A JP2020543742A JP2020543742A JP2021513552A JP 2021513552 A JP2021513552 A JP 2021513552A JP 2020543742 A JP2020543742 A JP 2020543742A JP 2020543742 A JP2020543742 A JP 2020543742A JP 2021513552 A JP2021513552 A JP 2021513552A
Authority
JP
Japan
Prior art keywords
drug
ibutamoren
ghs
effective amount
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020543742A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019161025A5 (enExample
Inventor
オリバー ソーナー マイケル
オリバー ソーナー マイケル
ジー．スミス ロイ
ジー．スミス ロイ
Original Assignee
ルーモス ファーマ，インコーポレイティド
ルーモス ファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルーモス ファーマ，インコーポレイティド, ルーモス ファーマ，インコーポレイティド filed Critical ルーモス ファーマ，インコーポレイティド
Publication of JP2021513552A publication Critical patent/JP2021513552A/ja
Publication of JPWO2019161025A5 publication Critical patent/JPWO2019161025A5/ja
Priority to JP2023221157A priority Critical patent/JP2024028337A/ja
Priority to JP2025129927A priority patent/JP2025179056A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020543742A 2018-02-14 2019-02-14 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 Withdrawn JP2021513552A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023221157A JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221157A Division JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Publications (2)

Publication Number Publication Date
JP2021513552A true JP2021513552A (ja) 2021-05-27
JPWO2019161025A5 JPWO2019161025A5 (enExample) 2022-02-21

Family

ID=67620042

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543742A Withdrawn JP2021513552A (ja) 2018-02-14 2019-02-14 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2023221157A Pending JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A Pending JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023221157A Pending JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A Pending JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Country Status (10)

Country Link
US (3) US20210059993A1 (enExample)
EP (3) EP4623929A3 (enExample)
JP (3) JP2021513552A (enExample)
KR (2) KR20240015742A (enExample)
CN (2) CN118453597A (enExample)
AU (2) AU2019222736B2 (enExample)
BR (1) BR112020016613A2 (enExample)
CA (1) CA3088177A1 (enExample)
EA (1) EA202091464A1 (enExample)
WO (1) WO2019161025A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025535941A (ja) * 2022-11-03 2025-10-30 ルーモス ファーマ，インコーポレイテッド イブタモレンの圧縮型経口製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799562B1 (en) 2019-03-29 2020-10-13 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease
KR20230079001A (ko) * 2020-09-18 2023-06-05 서울대학교산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521003A (ja) * 2008-06-03 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎａｆｌｄの治療における使用のためのｄｐｐ−ｉｖ阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2005042003A1 (en) * 2003-10-24 2005-05-12 Merck & Co., Inc. Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
CA2603295A1 (en) * 2004-04-07 2006-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
SG10201902137PA (en) * 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521003A (ja) * 2008-06-03 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎａｆｌｄの治療における使用のためのｄｐｐ−ｉｖ阻害剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GROWTH HORMONE AND IGF RESEARCH, vol. 37, JPN6023007891, 2017, pages 1 - 6, ISSN: 0005138681 *
INT. J. MOL. SCI., vol. 18, JPN6023007894, 2017, pages 1447 - 1, ISSN: 0005138682 *
J CLIN ENDOCRINOL METAB., vol. 84, JPN6023007896, 1999, pages 2028 - 2033, ISSN: 0005138683 *
J GASTROENTEROL., vol. 53, JPN6023007897, 2017, pages 362 - 376, ISSN: 0005138684 *
MED BULL HASEKI, 2017, VOL.55, P.286-291, JPN6023007890, ISSN: 0005000770 *
肝臓, vol. Vol.48 Suppl.1, JPN6023034822, 2007, pages 240 - 110, ISSN: 0005138685 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025535941A (ja) * 2022-11-03 2025-10-30 ルーモス ファーマ，インコーポレイテッド イブタモレンの圧縮型経口製剤

Also Published As

Publication number Publication date
JP2024028337A (ja) 2024-03-04
EP4467158A3 (en) 2025-02-19
CN118453597A (zh) 2024-08-09
KR20200121308A (ko) 2020-10-23
AU2019222736B2 (en) 2024-08-01
EP4623929A2 (en) 2025-10-01
EA202091464A1 (ru) 2020-12-07
US20230381158A1 (en) 2023-11-30
AU2019222736A1 (en) 2020-07-30
CA3088177A1 (en) 2019-08-22
AU2024205599A1 (en) 2024-08-22
EP3781158A1 (en) 2021-02-24
US20210059993A1 (en) 2021-03-04
EP3781158A4 (en) 2022-03-16
EP4623929A3 (en) 2025-12-17
EP4467158A2 (en) 2024-11-27
CN111727041A (zh) 2020-09-29
KR20240015742A (ko) 2024-02-05
JP2025179056A (ja) 2025-12-09
WO2019161025A1 (en) 2019-08-22
US20250281470A1 (en) 2025-09-11
BR112020016613A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
JP2021513552A (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
EP3132792B1 (en) Composition and methods for increasing insulin sensitivity
CN1178696C (zh) 含人体生长激素和皮质甾醇合成抑制剂的用于治疗代谢综合症的制剂
US20230084803A1 (en) Compositions and methods for treating metabolic diseases
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
EP3698801B1 (en) Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
JP2002543135A (ja) インスリン作用の増強方法
JP2009539803A (ja) ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤
US20150087588A1 (en) Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
Thakkar et al. Evogliptin tartrate a new drug of DPP-4 inhibitor: an overview
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
US20100305204A1 (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
WO2006108667A2 (en) Method of treatment using gh antagonist and somatostatin agonist
JP2005518437A (ja) 自己免疫疾患の治療のための生体エストリオール・スルファミン酸エステル・プロドラックの使用
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
CZ298999A3 (cs) Výroba léčiva, kombinovaný therapeutický prostředek a směs a kit obsahující inhibitor syntézy kortisolu a růstový hormon

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240905